Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity

Maike Marleen Holtsche; Nina Van Beek; Takashi Hashimoto; Giovanni Di Zenzo; Detlef Zillikens; Catherine Prost-Squarcioni; Matthias Titeux; Alain Hovnanian; Enno Schmidt; Stephanie Goletz

doi:10.2340/00015555-3774

Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity

Maike Marleen Holtsche, Nina Van Beek, Takashi Hashimoto, Giovanni Di Zenzo, Detlef Zillikens, Catherine Prost-Squarcioni, Matthias Titeux, Alain Hovnanian, Enno Schmidt, Stephanie Goletz^*

^*Korrespondierende/r Autor/-in für diese Arbeit

Abstract

Epidermolysis bullosa acquisita is a pemphigoid disease characterized by autoantibodies against type VII collagen. This study compared the sensitivity and specificity of 6 diagnostic assays: type VII collagen noncollagenous domains enzyme-linked immunoassay (NC1/2 ELISA) (MBL, Nagoya, Japan); type VII collagen NC1 ELISA (Euroimmun, Lübeck, Germany); indirect immunofluorescence (IF) microscopy test based on the expression of recombinant NC1 in a human cell line (NC1 BIOCHIP®; Euroimmun); full-length recombinant type VII collagen ELISA; immunoblotting with full-length type VII collagen in the extract of human dermis; and immunoblotting with recombinant NC1. Immunoblotting with recombinant NC1 showed a sensitivity of 93.1% and specificity of 100%, followed by NC1 BIOCHIP® (sensitivity, 89.1%; specificity, 100%), immunoblotting with human dermis (sensitivity, 87.1%; specificity 100%), NC1-ELISA (sensitivity 82.2%; specificity 98.6%), NC1/NC2 ELISA (sensitivity 88.1%; specificity 93.3%), and full-length type VII collagen ELISA (sensitivity 80.2%; specificity 93.8%).

Originalsprache	Englisch
Aufsatznummer	adv00420
Zeitschrift	Acta Dermato-Venereologica
Jahrgang	101
Ausgabenummer	3
Seiten (von - bis)	adv00420
ISSN	0001-5555
DOIs	https://doi.org/10.2340/00015555-3774
Publikationsstatus	Veröffentlicht - 2021

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)
Zentren: Center for Research on Inflammation of the Skin (CRIS)

DFG-Fachsystematik

2.21-05 Immunologie
2.22-19 Dermatologie

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

Dokumente

10.2340/00015555-3774

Weitere Links

Link to publication in Scopus

1 Abgeschlossen
1 Laufend

EXC 2167: Präzisionsmedizin für Chronische Entzündungserkrankungen (PMI)
Schreiber, S. (Sprecher*in, Koordinator*in), Baines, J. F. (Beteiligte*r Wissenschaftler*in), Bosch, T. C. G. (Beteiligte*r Wissenschaftler*in), Buyx, A. (Beteiligte*r Wissenschaftler*in), Erdmann, J. (Beteiligte*r Wissenschaftler*in), Franke, A. (Beteiligte*r Wissenschaftler*in), Huber, R. (Beteiligte*r Wissenschaftler*in), Klein, C. (Beteiligte*r Wissenschaftler*in), Köhl, J. (Beteiligte*r Wissenschaftler*in), König, I. R. (Beteiligte*r Wissenschaftler*in), Lange, C. (Beteiligte*r Wissenschaftler*in), Laudes, M. (Beteiligte*r Wissenschaftler*in), Lieb, W. (Beteiligte*r Wissenschaftler*in), Ludwig, R. (Beteiligte*r Wissenschaftler*in), Nebel, A. (Beteiligte*r Wissenschaftler*in), Niemann, S. (Beteiligte*r Wissenschaftler*in), Rabe, K. F. (Beteiligte*r Wissenschaftler*in), Riemekasten, G. (Beteiligte*r Wissenschaftler*in), Rose-John, S. (Beteiligte*r Wissenschaftler*in), Rosenstiel, P. C. (Beteiligte*r Wissenschaftler*in), Schulenburg, H. (Beteiligte*r Wissenschaftler*in), Schwarz, K. (Beteiligte*r Wissenschaftler*in), Traulsen, A. (Beteiligte*r Wissenschaftler*in), Weidinger, S. (Beteiligte*r Wissenschaftler*in) & Zillikens, D. (Beteiligte*r Wissenschaftler*in)
01.01.19 → …
Projekt: DFG-Projekte › DFG Exzellenzcluster
KFO 303: Pemphigoid Diseases - Molecular Pathways and their Therapeutic Potential
Sadik, C. (Sprecher*in, Koordinator*in), Zillikens, D. (Sprecher*in, Koordinator*in), Ibrahim, S. (Projektleiter*in (PI)), Baines, J. F. (Projektleiter*in (PI)), Schmidt, E. (Projektleiter*in (PI)), Köhl, J. (Projektleiter*in (PI)), Ehlers, M. (Projektleiter*in (PI)), Hirose, M. (Projektleiter*in (PI)), König, P. (Projektleiter*in (PI)), Ludwig, R. (Projektleiter*in (PI)), Manz, R. (Projektleiter*in (PI)), Schwaninger, M. (Projektleiter*in (PI)), Beek, N. (Projektleiter*in (PI)), Erdmann, J. (Projektleiter*in (PI)), König, I. R. (Projektleiter*in (PI)), Verschoor, A. (Projektleiter*in (PI)), Karsten, C. (Projektleiter*in (PI)), Bieber, K. (Projektleiter*in (PI)) & Busch, H. S. (Projektleiter*in (PI))
01.04.15 → 31.12.23
Projekt: DFG-Projekte › DFG-Verbundforschung: Forschergruppen/Klinische Forschergruppen

Zitieren

Holtsche, M. M., Van Beek, N., Hashimoto, T., Di Zenzo, G., Zillikens, D., Prost-Squarcioni, C., Titeux, M., Hovnanian, A., Schmidt, E., & Goletz, S. (2021). Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity. Acta Dermato-Venereologica, 101(3), adv00420. Artikel adv00420. https://doi.org/10.2340/00015555-3774

@article{50a11e6ce627442ab4066d0b00e5285e,

title = "Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity",

abstract = "Epidermolysis bullosa acquisita is a pemphigoid disease characterized by autoantibodies against type VII collagen. This study compared the sensitivity and specificity of 6 diagnostic assays: type VII collagen noncollagenous domains enzyme-linked immunoassay (NC1/2 ELISA) (MBL, Nagoya, Japan); type VII collagen NC1 ELISA (Euroimmun, L{\"u}beck, Germany); indirect immunofluorescence (IF) microscopy test based on the expression of recombinant NC1 in a human cell line (NC1 BIOCHIP{\textregistered}; Euroimmun); full-length recombinant type VII collagen ELISA; immunoblotting with full-length type VII collagen in the extract of human dermis; and immunoblotting with recombinant NC1. Immunoblotting with recombinant NC1 showed a sensitivity of 93.1% and specificity of 100%, followed by NC1 BIOCHIP{\textregistered} (sensitivity, 89.1%; specificity, 100%), immunoblotting with human dermis (sensitivity, 87.1%; specificity 100%), NC1-ELISA (sensitivity 82.2%; specificity 98.6%), NC1/NC2 ELISA (sensitivity 88.1%; specificity 93.3%), and full-length type VII collagen ELISA (sensitivity 80.2%; specificity 93.8%).",

author = "Holtsche, {Maike Marleen} and {Van Beek}, Nina and Takashi Hashimoto and {Di Zenzo}, Giovanni and Detlef Zillikens and Catherine Prost-Squarcioni and Matthias Titeux and Alain Hovnanian and Enno Schmidt and Stephanie Goletz",

year = "2021",

doi = "10.2340/00015555-3774",

language = "English",

volume = "101",

pages = "adv00420",

journal = "Acta Dermato-Venereologica",

issn = "0001-5555",

number = "3",

}

Holtsche, MM , Van Beek, N, Hashimoto, T, Di Zenzo, G, Zillikens, D, Prost-Squarcioni, C, Titeux, M, Hovnanian, A, Schmidt, E & Goletz, S 2021, 'Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity', Acta Dermato-Venereologica, Jg. 101, Nr. 3, adv00420, S. adv00420. https://doi.org/10.2340/00015555-3774

Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity. / Holtsche, Maike Marleen ; Van Beek, Nina; Hashimoto, Takashi et al.
in: Acta Dermato-Venereologica, Jahrgang 101, Nr. 3, adv00420, 2021, S. adv00420.

Publikation: Beiträge in Fachzeitschriften › Zeitschriftenaufsätze › Forschung › Begutachtung

TY - JOUR

T1 - Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity

AU - Holtsche, Maike Marleen

AU - Van Beek, Nina

AU - Hashimoto, Takashi

AU - Di Zenzo, Giovanni

AU - Zillikens, Detlef

AU - Prost-Squarcioni, Catherine

AU - Titeux, Matthias

AU - Hovnanian, Alain

AU - Schmidt, Enno

AU - Goletz, Stephanie

PY - 2021

Y1 - 2021

N2 - Epidermolysis bullosa acquisita is a pemphigoid disease characterized by autoantibodies against type VII collagen. This study compared the sensitivity and specificity of 6 diagnostic assays: type VII collagen noncollagenous domains enzyme-linked immunoassay (NC1/2 ELISA) (MBL, Nagoya, Japan); type VII collagen NC1 ELISA (Euroimmun, Lübeck, Germany); indirect immunofluorescence (IF) microscopy test based on the expression of recombinant NC1 in a human cell line (NC1 BIOCHIP®; Euroimmun); full-length recombinant type VII collagen ELISA; immunoblotting with full-length type VII collagen in the extract of human dermis; and immunoblotting with recombinant NC1. Immunoblotting with recombinant NC1 showed a sensitivity of 93.1% and specificity of 100%, followed by NC1 BIOCHIP® (sensitivity, 89.1%; specificity, 100%), immunoblotting with human dermis (sensitivity, 87.1%; specificity 100%), NC1-ELISA (sensitivity 82.2%; specificity 98.6%), NC1/NC2 ELISA (sensitivity 88.1%; specificity 93.3%), and full-length type VII collagen ELISA (sensitivity 80.2%; specificity 93.8%).

AB - Epidermolysis bullosa acquisita is a pemphigoid disease characterized by autoantibodies against type VII collagen. This study compared the sensitivity and specificity of 6 diagnostic assays: type VII collagen noncollagenous domains enzyme-linked immunoassay (NC1/2 ELISA) (MBL, Nagoya, Japan); type VII collagen NC1 ELISA (Euroimmun, Lübeck, Germany); indirect immunofluorescence (IF) microscopy test based on the expression of recombinant NC1 in a human cell line (NC1 BIOCHIP®; Euroimmun); full-length recombinant type VII collagen ELISA; immunoblotting with full-length type VII collagen in the extract of human dermis; and immunoblotting with recombinant NC1. Immunoblotting with recombinant NC1 showed a sensitivity of 93.1% and specificity of 100%, followed by NC1 BIOCHIP® (sensitivity, 89.1%; specificity, 100%), immunoblotting with human dermis (sensitivity, 87.1%; specificity 100%), NC1-ELISA (sensitivity 82.2%; specificity 98.6%), NC1/NC2 ELISA (sensitivity 88.1%; specificity 93.3%), and full-length type VII collagen ELISA (sensitivity 80.2%; specificity 93.8%).

UR - http://www.scopus.com/inward/record.url?scp=85103130698&partnerID=8YFLogxK

U2 - 10.2340/00015555-3774

DO - 10.2340/00015555-3774

M3 - Journal articles

C2 - 33686442

AN - SCOPUS:85103130698

SN - 0001-5555

VL - 101

SP - adv00420

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

IS - 3

M1 - adv00420

ER -

Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity

Abstract

Strategische Forschungsbereiche und Zentren

DFG-Fachsystematik

UN SDGs

Dokumente

Weitere Links

Fingerprint

Projekte

EXC 2167: Präzisionsmedizin für Chronische Entzündungserkrankungen (PMI)

KFO 303: Pemphigoid Diseases - Molecular Pathways and their Therapeutic Potential

Zitieren